We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Tilray Brands, Inc. (TLRY) Laps the Stock Market: Here's Why
Read MoreHide Full Article
Tilray Brands, Inc. (TLRY - Free Report) closed at $4.08 in the latest trading session, marking a +2.26% move from the prior day. The stock outpaced the S&P 500's daily gain of 1.49%. Meanwhile, the Dow experienced a rise of 0.71%, and the technology-dominated Nasdaq saw an increase of 2.26%.
The company's stock has dropped by 17.56% in the past month, falling short of the Medical sector's loss of 1.14% and the S&P 500's gain of 0.1%.
The upcoming earnings release of Tilray Brands, Inc. will be of great interest to investors. Simultaneously, our latest consensus estimate expects the revenue to be $268.23 million, showing a 28.03% escalation compared to the year-ago quarter.
TLRY's full-year Zacks Consensus Estimates are calling for earnings of -$0.42 per share and revenue of $1.1 billion. These results would represent year-over-year changes of +61.47% and +20.56%, respectively.
Investors might also notice recent changes to analyst estimates for Tilray Brands, Inc. These revisions help to show the ever-changing nature of near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has remained steady. At present, Tilray Brands, Inc. boasts a Zacks Rank of #3 (Hold).
The Medical - Products industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 92, finds itself in the top 38% echelons of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
View the Zacks #1 Rank List
Image: Bigstock
Tilray Brands, Inc. (TLRY) Laps the Stock Market: Here's Why
Tilray Brands, Inc. (TLRY - Free Report) closed at $4.08 in the latest trading session, marking a +2.26% move from the prior day. The stock outpaced the S&P 500's daily gain of 1.49%. Meanwhile, the Dow experienced a rise of 0.71%, and the technology-dominated Nasdaq saw an increase of 2.26%.
The company's stock has dropped by 17.56% in the past month, falling short of the Medical sector's loss of 1.14% and the S&P 500's gain of 0.1%.
The upcoming earnings release of Tilray Brands, Inc. will be of great interest to investors. Simultaneously, our latest consensus estimate expects the revenue to be $268.23 million, showing a 28.03% escalation compared to the year-ago quarter.
TLRY's full-year Zacks Consensus Estimates are calling for earnings of -$0.42 per share and revenue of $1.1 billion. These results would represent year-over-year changes of +61.47% and +20.56%, respectively.
Investors might also notice recent changes to analyst estimates for Tilray Brands, Inc. These revisions help to show the ever-changing nature of near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has remained steady. At present, Tilray Brands, Inc. boasts a Zacks Rank of #3 (Hold).
The Medical - Products industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 92, finds itself in the top 38% echelons of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.